NCT03897088

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 231 (actual)
• Sponsor: Sun Pharmaceutical Industries Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.

Conditions

• Scalp Psoriasis

Interventions

Type	Name	Description
DRUG	PART 1: Double-blind Placebo-controlled	all eligible subjects will receive either tildrakizumab or placebo
DRUG	PART 2: Double-blind Active Treatment Extension	subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule

Timeline

• Start date: 2019-03-29
• Primary completion: 2022-02-17
• Completion: 2022-02-17
• First posted: 2019-04-01
• Last updated: 2023-05-31
• Results posted: 2023-05-31

Locations

25 sites across 2 countries: United States, Australia

Regulatory

• FDA-regulated drug study